B1.1 Composition of Dental Composite (6 marks)

1. Organic Resin Matrix (Monomer System)

• Base monomers (dimethacrylates): The most widely used is Bis-GMA (bisphenol A-glycidyl dimethacrylate, Bowen's monomer), which provides rigidity and low polymerization shrinkage. Other base monomers include UDMA (urethane dimethacrylate) and TEGDMA (triethylene glycol dimethacrylate). TEGDMA is used as a diluent to reduce the high viscosity of Bis-GMA.
• Photoinitiator system: Camphorquinone (CQ) is the most common photoinitiator, absorbing light at ~470 nm (blue light). It works alongside a co-initiator/amine accelerator (e.g., DMAEMA — dimethylaminoethyl methacrylate) to generate free radicals upon light activation.
• Inhibitors: Small amounts of hydroquinone or BHT (butylated hydroxytoluene) are added to prevent premature, spontaneous polymerization during storage (shelf-life stabilization).

2. Inorganic Filler Phase

• Filler particles: Most commonly quartz, barium glass, strontium glass, or silica. These are radiopaque (barium/strontium) to allow radiographic detection.
• Filler size and type determine the classification:
  • Macrofilled: 1–100 µm particles (poor polishability)
  • Microfilled: 0.01–0.1 µm colloidal silica (excellent polish, weaker)
  • Hybrid/Nanohybrid: Combination of micro and macro/nano fillers (most common clinically — balances strength and aesthetics)
  • Nanofilled: Nanoparticles <100 nm (superior polish and strength)
• Filler content: Typically 60–80% by weight (40–70% by volume).

3. Coupling Agent (Interface Phase)

• Silane coupling agent (e.g., 3-methacryloxypropyltrimethoxysilane) is applied to the filler surface to create a covalent chemical bond between the inorganic filler and organic resin matrix. This bond transfer improves mechanical properties (flexural strength, fracture toughness) and reduces water sorption at the filler–matrix interface.

4. Optional Additives

• Opacifiers (e.g., TiO₂, Al₂O₃) — for shade matching and masking translucency
• Pigments/dyes — for color matching to tooth structure
• UV absorbers — to reduce color degradation from ambient light
• Fluoride-releasing agents (in some formulations) — for caries prevention

B1.2 Two Methods to Reduce Polymerization Shrinkage (4 marks)

Method 1: Use of High-Molecular-Weight and Low-Shrinkage Monomers

• High-molecular-weight monomers such as Bis-GMA or UDMA: These have fewer reactive double bonds per unit volume (lower molar conversion per volume), intrinsically reducing volumetric shrinkage.
• Ring-opening monomers (e.g., spiro-orthocarbonates, oxetanes): Unlike methacrylates, these expand slightly during polymerization (the ring opens and increases volume), partially compensating for the overall shrinkage. Incorporating these as co-monomers can reduce net shrinkage significantly.
• Silorane-based monomers (e.g., Filtek Silorane, 3M): These are cationic ring-opening monomers derived from siloxane and oxirane chemistry. Their ring-opening polymerization produces minimal shrinkage (~0.94% volumetric shrinkage vs. ~2–3% for conventional methacrylate composites), resulting in lower stress at cavity margins.

Method 2: Incremental Placement Technique (Layering Technique)

• The composite is placed in thin increments (≤2 mm each) and each increment is individually light-cured before the next is applied.
• This reduces the C-factor (configuration factor) — the ratio of bonded surfaces to free surfaces. A lower C-factor means less constrained shrinkage, so stress at the tooth–restoration interface is reduced.
• The oblique incremental technique is particularly effective: each increment has fewer bonded walls, allowing it to flow slightly during polymerization before setting, relieving stress.
• This prevents the overall shrinkage of a bulk-filled restoration from pulling away from cavity walls simultaneously, thereby minimizing marginal gaps, microleakage, and post-operative sensitivity.

Additional note: Modern bulk-fill composites (e.g., SonicFill, SDR) are engineered with modified monomers and stress-relieving modulators (pre-polymerized filler particles, flexibilizer molecules) to allow placement in a single 4–5 mm increment while maintaining acceptable shrinkage stress.

Clinical Case Analysis

IOPAR Findings

• Most posterior tooth (likely 16/upper right first molar): A large, dense radiopaque restoration (amalgam or metal crown/MOD restoration) present occlusally and proximally — bright white area indicating a metallic restoration.
• Adjacent premolar/second premolar area: Appears to show a radiolucent area at the interproximal contact — suggestive of interproximal (proximal) caries or an existing restoration with secondary caries.
• Periodontal ligament space: Appears within normal limits on all visible teeth.
• Periapical region: No periapical radiolucency visible — no evidence of periapical pathology.
• Crestal bone levels: Appear within normal limits — no significant bone loss.
• Root canal spaces: Appear normal; no internal/external resorption seen.

Diagnosis

Justification:

• Reversible pulpitis: Pain provoked, resolves within seconds of removing stimulus → pulp is inflamed but vital and capable of healing.
• Irreversible pulpitis: Pain lingers for >30 seconds or occurs spontaneously → indicates advanced pulpal breakdown requiring root canal treatment.

Treatment Plan

1. Caries Removal and Restoration

• Excavate all carious dentine using slow-speed round bur or caries removal instruments, following a minimally invasive approach.
• Cavity preparation following principles of minimal intervention dentistry.

2. Pulp Protection

• Since the caries is likely close to (but not involving) the pulp:
  • Indirect pulp capping if near-pulp exposure is expected — application of a biocompatible calcium silicate cement (e.g., MTA or Biodentine) or calcium hydroxide over the deepest dentine, followed by a base/liner.
  • If remaining dentine thickness (RDT) is adequate (>0.5 mm), a liner may not be mandatory.

3. Definitive Restoration

• Composite resin restoration (tooth-coloured, adhesive) — preferred for a 25-year-old for aesthetic and conservative reasons.
• Dental adhesive system (etch-and-rinse or self-etch) applied prior to composite placement.
• Incremental layering technique to minimize polymerization shrinkage (as discussed in B1.2).

4. Recall and Review

• Review at 6–8 weeks to confirm:
  • Symptoms have resolved
  • Positive response to vitality testing (cold/EPT)
  • No development of spontaneous pain (which would indicate progression to irreversible pulpitis and necessitate root canal treatment)

Summary

B2.1 Diagnostic Tests for Reversible Pulpitis

1. Thermal Tests (Pulp Vitality Testing)

a) Cold Test (most relevant here)

• Method: A cotton pellet sprayed with refrigerant spray (1,1,1,2-tetrafluoroethane, -26°C) or an ice stick is applied to the middle third of the buccal surface of the tooth.
• Positive response in reversible pulpitis: Sharp, momentary pain that resolves within a few seconds of removing the stimulus.
• Interpretation: A lingering response (>30 seconds) would indicate irreversible pulpitis; no response would suggest pulp necrosis.
• Control: Always test a healthy contralateral tooth first to establish a baseline response.

b) Heat Test

• Method: A heated gutta-percha stick or warm water is applied to the tooth surface.
• Less relevant here as the patient's complaint is specifically cold and sweet sensitivity, but used to rule out irreversible pulpitis (which typically shows exaggerated, lingering pain to heat).

2. Electrical Pulp Test (EPT)

• Method: A small electrical current is passed through the tooth via an electrode placed on the dried, isolated tooth surface (with conducting gel). Current is gradually increased until the patient feels a tingling sensation.
• Purpose: Confirms pulp vitality — tests the integrity of A-δ nerve fibers rather than vascularity.
• Response in reversible pulpitis: Response at a normal or slightly elevated threshold compared to the contralateral control tooth — confirming a vital, inflamed pulp.
• Limitation: EPT confirms vitality (nerve function) but does not indicate the degree of inflammation; false results possible in calcified canals, recently traumatized teeth, or patients on certain medications.

3. Selective Anesthesia

• Method: Local anaesthetic is administered selectively — starting with an infiltration at the suspected tooth, progressing to block if needed.
• Purpose: Used when the patient cannot localize the offending tooth (especially in the posterior region where referred pain is common).
• Interpretation: If pain is eliminated after anesthetizing a specific tooth or quadrant, it confirms that tooth/region as the source.
• Relevance here: The patient has localized the pain to the upper right quadrant, so this test helps confirm the exact tooth if clinical and radiographic findings are equivocal.

4. Percussion and Palpation Tests

• Percussion: Gentle tapping on the occlusal/incisal surface with a mirror handle.
  • Expected finding in reversible pulpitis: No pain or mild discomfort — significant pain would suggest periapical involvement (periodontitis).
• Palpation: Firm pressure applied to the mucosa overlying the apex.
  • Expected finding: No tenderness — confirms normal periapical tissues, consistent with the IOPAR showing no periapical lucency.

5. Cavity/Dentin Sensitivity Test (Tactile/Explorer Test)

• Method: A sharp explorer is run across exposed dentine, cavity margins, or suspected carious area.
• Finding: Elicits a sharp, transient pain upon touching the affected dentine — confirms dentinal hypersensitivity and helps identify the specific tooth surface involved.
• Radiographic correlation: Combined with the IOPAR findings of interproximal caries, this test localizes the lesion precisely.

Summary Table

Key diagnostic criterion: Pain that is provoked, sharp, and brief (non-lingering) across all tests confirms reversible pulpitis and distinguishes it from irreversible pulpitis or pulp necrosis.

B2.2 Management Strategies for Reversible Pulpitis with Caries (7 Marks)

Step 1: Patient Education and Oral Hygiene Instructions (OHI)

• Educate the patient on the aetiology of caries — plaque accumulation, dietary sugars, acid demineralisation.
• Advise dietary modifications — reducing frequency of fermentable carbohydrates and acidic beverages.
• Demonstrate correct toothbrushing technique (Modified Bass technique) and interdental cleaning (floss/interdental brushes) — critical for interproximal caries prevention.
• Prescribe fluoride toothpaste (1000–1450 ppm) twice daily — promotes remineralisation and reduces dentinal sensitivity.
• Explain the proposed treatment plan, obtain informed consent.

Step 2: Local Anaesthesia

• Administer infiltration anaesthesia (e.g., 2% lidocaine with 1:100,000 adrenaline) in the upper right buccal sulcus adjacent to the affected tooth.
• Ensures pain-free operative procedure and patient cooperation.
• In maxillary teeth, buccal infiltration alone is usually sufficient due to thin cortical bone; palatal infiltration added if required.

Step 3: Caries Removal — Minimally Invasive Approach

• Rubber dam isolation — mandatory for moisture control, preventing contamination, and protecting the airway.
• Use a slow-speed round tungsten carbide bur or polymer bur (e.g., Carisolv or SmartBurs) to selectively remove carious dentine:
  • Outer infected dentine (irreversibly denatured collagen, heavily bacterially contaminated) — must be completely removed.
  • Inner affected dentine (demineralised but collagen intact, bacteria-free) — can be preserved, especially near the pulp, to maintain the dentinal barrier.
• Caries detection dye (1% acid red in propylene glycol) may be used to distinguish infected from affected dentine — dye stains only infected dentine red.
• Principle: Remove all caries on the enamel-dentine junction (DEJ) and peripheral walls; preserve deeper affected dentine near the pulp.

Step 4: Pulp Management Strategy

A. No Near-Pulp Exposure — Liner Only

• If RDT is adequate (>0.5 mm) and no near-exposure suspected:
  • Apply a thin layer of calcium hydroxide liner or glass ionomer cement (GIC) base over deep dentine.
  • Proceed directly to bonding and restoration.

B. Near-Pulp Exposure — Indirect Pulp Capping (IPC)

• If caries approaches the pulp but no frank exposure is present:
  • Apply Biodentine (calcium silicate cement) or MTA (Mineral Trioxide Aggregate) directly over the deepest, soft affected dentine.
  • These materials are biocompatible, bactericidal, and stimulate tertiary (reparative) dentinogenesis by activating pulpal stem cells to lay down a dentine bridge.
  • MTA/Biodentine are preferred over calcium hydroxide for IPC due to superior sealing ability and more predictable long-term outcomes.
  • A layer of GIC or resin-modified GIC (RMGIC) is then placed over the capping material as a base before bonding.

C. Pulp Exposure (Mechanical/Carious) — Direct Pulp Capping

• If a small mechanical exposure (<1 mm) occurs in a young vital tooth with no signs of irreversible pulpitis:
  • Control haemorrhage with sterile saline-moistened cotton pellets (not hydrogen peroxide).
  • Apply MTA or Biodentine directly over the exposure site.
  • Definitive restoration placed after material sets.
  • Note: Carious (infected) exposures carry a poorer prognosis for pulp capping — root canal therapy may be preferred in such cases.

Step 5: Cavity Conditioning and Bonding

• Acid etching: 37% phosphoric acid applied — 15 seconds on dentine, 30 seconds on enamel — or use self-etch adhesive to reduce post-operative sensitivity.
• Bonding agent applied and light-cured per manufacturer's instructions:
  • Total-etch (etch-and-rinse) system — e.g., Adper Single Bond, OptiBond
  • Self-etch system — e.g., Clearfil SE Bond — gentler on near-pulp dentine, reduces risk of postoperative sensitivity (preferred in deep cavities).
• Bonding creates a hybrid layer — resin tags interlock with demineralised dentinal collagen, forming a micro-mechanical seal that prevents microleakage and secondary caries.

Step 6: Definitive Restoration — Composite Resin

• Material choice: Tooth-coloured nanohybrid or nanofilled composite resin — optimal balance of aesthetics, strength, and polishability.
• Placement technique:
  • Incremental layering (≤2 mm per increment) to minimize polymerization shrinkage stress (as discussed in B1.2).
  • Oblique incremental technique for posterior teeth.
  • Each increment light-cured for adequate time (typically 20–40 seconds at >600 mW/cm²).
• Shade selection done prior to isolation while tooth is hydrated.
• Contouring and finishing: Carbide finishing burs → finishing discs → polishing pastes to achieve smooth margins, proper contact points, and anatomy.
• Occlusal adjustment: Articulating paper used to check and adjust occlusion — no premature contacts or interferences.

Step 7: Desensitising Agents (Adjunct Management)

• Topical fluoride varnish (5% NaF / Duraphat) — occludes dentinal tubules, promotes remineralisation.
• Potassium nitrate-containing desensitiser — depolarises nerve endings, reducing pain transmission.
• Dentine bonding agent applied to exposed cervical dentine if hypersensitivity persists.

Step 8: Review and Follow-Up

• 6–8 week review:
  • Assess symptoms — resolution of sharp pain confirms successful management.
  • Repeat cold and EPT testing — continued positive vital response confirms pulp health.
  • If pain has progressed to spontaneous, lingering, or nocturnal pain → diagnosis upgraded to irreversible pulpitis → root canal treatment required.
• 6-month and 1-year recall:
  • Radiographic check — no periapical changes, no secondary caries, intact margins.
  • Reassess restoration margins clinically.

Summary of Management Algorithm

Caries Diagnosed (Reversible Pulpitis)
           ↓
   OHI + Dietary Advice
           ↓
   Local Anaesthesia + Rubber Dam
           ↓
   Selective Caries Removal (MID)
           ↓
   ┌───────────────────────────┐
   │  Assess Pulp Proximity    │
   └───────────────────────────┘
     ↓              ↓              ↓
  RDT adequate   Near-pulp      Exposure
  → GIC base   → Indirect PC  → Direct PC
                (Biodentine)   (MTA/Biodentine)
           ↓
   Bonding Agent (Self-etch preferred)
           ↓
   Nanohybrid Composite (Incremental)
           ↓
   Finish, Polish, Occlusal Check
           ↓
   Review at 6–8 weeks
           ↓
  Symptoms resolved? → Discharge to recall
  Symptoms worsened? → Root Canal Treatment

Prognosis

B3.1 Diagnosis (2 Marks)

Pulpal Diagnosis: Pulp Necrosis

Periapical Diagnosis: Symptomatic Apical Periodontitis (likely with Chronic Apical Abscess / Periapical Pathology)

Clinical Reasoning:

• Thin, fragile dentinal walls
• Blunderbuss (wide open) or divergent apical foramen
• Incomplete root length

B3.2 Treatment Options in Detail (8 Marks)

1. Eliminate infection and periapical pathology
2. Manage the immature root (open apex, thin walls) — conventional root canal obturation with gutta-percha is not possible without an apical stop

Pre-Treatment Assessment

• IOPAR / CBCT: Assess root length, apical foramen diameter, periapical lesion size, root wall thickness. CBCT preferred for 3D assessment of complex periapical lesions.
• Vitality tests: Cold test and EPT — expected no response (confirms necrosis).
• Percussion: Likely positive (tender to percussion — confirms symptomatic apical periodontitis).
• Palpation: May reveal fluctuant swelling if abscess has formed, or tenderness over the apex.
• Sinus tract: Check for presence of parulis/sinus tract on labial gingiva — if present, trace with gutta-percha cone and radiograph.

Treatment Option 1: Apexification with Calcium Hydroxide (Traditional)

• Kills residual bacteria and neutralises bacterial lipopolysaccharides (LPS)
• Stimulates apical hard tissue barrier formation (calcific bridge) via activity of undifferentiated mesenchymal cells in the periapical tissues

1. Administer local anaesthesia; rubber dam isolation.
2. Access cavity preparation through the palatal surface.
3. Minimal instrumentation — use large files gently with copious 2.5% NaOCl irrigation (antibacterial) to remove necrotic pulp tissue. Avoid aggressive filing due to thin dentinal walls (risk of perforation/fracture).
4. Dry the canal with paper points.
5. Pack Ca(OH)₂ paste (e.g., Metapex, Ultracal) to the working length using a lentulo spiral or syringe.
6. Seal with GIC or RMGIC temporary restoration.
7. Review every 3 months — replace Ca(OH)₂ dressing; radiographically assess for apical barrier formation.
8. Once a calcific apical barrier is confirmed (typically 6–24 months), obturate with gutta-percha and sealer.

• Long treatment time (months to years)
• Multiple appointments
• Prolonged Ca(OH)₂ use weakens dentine (cervical fracture risk — hydrolysis of collagen)
• Barrier formed is porous ("Swiss cheese" histology), not true cementum

Treatment Option 2: Apexification with MTA Plug (One-Visit) ⭐ Preferred

• Excellent biocompatibility and bioactivity
• Stimulates cementogenesis and bone regeneration
• Superior sealing ability (minimal microleakage)
• Sets in presence of moisture
• Radiopaque (bismuth oxide)

1. Local anaesthesia; rubber dam isolation.
2. Access preparation; copious irrigation with NaOCl + EDTA (17% EDTA removes smear layer, exposes dentinal tubules, releases growth factors from dentine matrix).
3. If large periapical lesion: consider calcium hydroxide dressing for 1–4 weeks first to disinfect and reduce inflammation before MTA placement.
4. Dry canal; place MTA using a MAP (MTA Applicator) or amalgam carrier:
   • Condense a 4–5 mm apical plug of MTA at the apex using pluggers.
   • Confirm placement radiographically.
5. Place moist cotton pellet; seal with GIC temporarily for 24–48 hours to allow MTA to set.
6. At next visit — confirm set MTA; obturate remainder of canal with thermoplasticised gutta-percha (warm vertical compaction) or use Biodentine to fill entire canal if walls are very thin.
7. Final coronal restoration — composite resin or full coverage crown if tooth is weakened.

• Predictable apical seal in 1–2 visits
• No prolonged dentinal weakening
• Superior biocompatibility and regenerative potential

Treatment Option 3: Regenerative Endodontic Procedure (REP) / Pulp Revascularisation ⭐⭐ Most Biologically Ideal

• The Stem Cells of the Apical Papilla (SCAP) survive even when the pulp is necrotic (they are located beyond the apex in the apical papilla).
• REP aims to introduce a blood clot scaffold into the disinfected root canal space, which becomes colonised by SCAP and other stem cells → leading to continued root development (root lengthening, dentinal wall thickening, apex closure).
• This is the only treatment that can achieve true root maturation rather than just apical closure.

1. Local anaesthesia (avoid lidocaine with adrenaline — use 3% mepivacaine plain or minimal vasoconstrictor to preserve stem cells); rubber dam.
2. Access preparation; minimal instrumentation (NEVER over-instrument — preserve thin walls).
3. Copious irrigation:
   • 1.5% NaOCl (reduced concentration to preserve SCAP viability — full strength is cytotoxic)
   • 17% EDTA — releases dentine matrix proteins (BMPs, TGF-β) that support stem cell differentiation
   • Final rinse: 17% EDTA preferred over NaOCl as final irrigant
4. Dry canal with paper points.
5. Place Triple Antibiotic Paste (TAP) — Metronidazole + Ciprofloxacin + Minocycline (1:1:1) into canal to working length — OR Double Antibiotic Paste (DAP) — Metronidazole + Ciprofloxacin (omitting minocycline to avoid tooth crown discoloration in anterior tooth).
   • Alternative: Calcium hydroxide (less effective but avoids discolouration risk).
6. Seal coronally with GIC temporary restoration.
7. Review at 4 weeks.

1. Remove antibiotic paste with EDTA irrigation.
2. Induce bleeding into the canal:
   • Insert a pre-curved K-file 2 mm beyond the apex into periapical tissues to lacerate blood vessels.
   • Allow blood to fill canal to 3 mm below CEJ level.
   • Wait 15 minutes for blood clot (scaffold) to form.
   • Alternative scaffolds: PRP (Platelet Rich Plasma), PRF (Platelet Rich Fibrin), or collagen sponge.
3. Place white MTA or Biodentine (3–4 mm) over the blood clot at the CEJ level to create a coronal seal/plug.
4. Place moist cotton pellet → GIC → allow MTA to set.
5. At follow-up: Definitive composite resin restoration to seal access cavity.

• Continued root lengthening
• Thickening of dentinal walls
• Apical closure / narrowing
• Resolution of periapical lesion

Choosing Between Treatment Options

Post-Treatment Management

• Antibiotic cover: If acute abscess/swelling present — systemic Amoxicillin 500 mg TDS × 5–7 days (or Metronidazole 400 mg TDS if penicillin allergy).
• Analgesics: Ibuprofen 400 mg TDS for pain management.
• Long-term radiographic follow-up: At 6, 12, 18, 24 months — monitor root development, periapical healing, and absence of symptoms.
• Coronal restoration: A well-sealed final restoration is critical — coronal leakage is a leading cause of REP/endodontic failure.
• Trauma prevention: Mouthguard fabrication for sports activities.
• Patient counselling: Young patient must understand the importance of follow-up and that the tooth, while salvageable, remains at higher fracture risk than an uninjured tooth.

Conclusion

• Maxillary central incisor (likely 21) shows a wide open apex (blunderbuss canal) with thin divergent root walls — confirms root development was arrested at time of trauma (age ~9)
• Large periapical radiolucency around the apex — chronic periapical abscess/granuloma with acute exacerbation
• Root canal space appears wide and immature
• Adjacent teeth appear vital with normal apices

• Fractured/chipped maxillary left central incisor (21) — consistent with old traumatic injury (9 years ago)
• Parulis (sinus tract opening / gum boil) visible on the labial gingiva above tooth 21 — yellowish/raised nodule indicating a draining chronic abscess
• Crown appears discoloured compared to adjacent teeth
• No obvious soft tissue swelling suggesting the infection is currently draining through the sinus tract

B3.1 Diagnosis (2 Marks)

Pulpal Diagnosis: Pulp Necrosis

Periapical Diagnosis: Chronic Apical Abscess with Sinus Tract (Acute Exacerbation — "Phoenix Abscess")

Additional Finding: Immature Root with Open Apex (Incomplete Rhizogenesis)

Diagnostic Justification:

B3.2 Treatment Options in Detail (8 Marks)

1. Necrotic infected pulp with periapical pathology requiring elimination
2. Immature open apex — conventional gutta-percha obturation impossible without an apical stop; thin fragile dentinal walls at high fracture risk

Option 1: Long-Term Calcium Hydroxide Apexification (Traditional — Less Preferred)

1. Local anaesthesia (infiltration — maxillary anterior); rubber dam isolation
2. Access cavity through palatal surface of crown
3. Establish working length (radiographically — 1 mm short of radiographic apex)
4. Minimal instrumentation with large files — only enough to remove necrotic debris (do NOT over-instrument thin walls)
5. Copious irrigation:
   • 2.5% NaOCl — tissue dissolution, antimicrobial
   • 17% EDTA — smear layer removal, releases dentine matrix growth factors
   • Final rinse with saline or chlorhexidine 2%
6. Dry with paper points
7. Introduce Ca(OH)₂ paste (Metapex/Ultracal XS) to working length via lentulo spiral
8. Seal with GIC temporary restoration
9. Review every 3 months — replace Ca(OH)₂; assess radiographically

• Treatment duration: 6 months to 2 years
• Prolonged Ca(OH)₂ weakens dentine via protein hydrolysis → increased risk of cervical root fracture
• Barrier formed is porous and irregular ("Swiss cheese" histology)
• Multiple appointments; patient compliance required

Option 2: MTA Apical Plug — One-Visit Apexification ⭐ (Preferred over Ca(OH)₂)

• Sets in moisture (relevant as periapical exudate may be present)
• Biocompatible and bioactive — stimulates cementum and bone regeneration at the apex
• Excellent marginal seal (minimal microleakage)
• Radiopaque (bismuth oxide component)
• pH ~12.5 — antibacterial

• Canal disinfection with NaOCl + EDTA irrigation
• Place Ca(OH)₂ dressing for 2–4 weeks to reduce microbial load and periapical inflammation before MTA placement (particularly important given the large periapical lesion and sinus tract)
• GIC temporary seal

1. Remove Ca(OH)₂; re-irrigate with NaOCl then EDTA
2. Dry canal with paper points
3. Deliver MTA using MAP system (MTA Applicator) or amalgam carrier into apical 4–5 mm
4. Condense with pluggers cut to working length — confirm placement with periapical radiograph
5. Place moist cotton pellet over MTA → seal with GIC temporarily (24–48 hours for MTA to set)

1. Confirm MTA set (probe with explorer)
2. Obturate remaining canal space:
   • Thermoplasticised gutta-percha (warm vertical compaction) — if walls are adequate
   • OR Biodentine/MTA fill of entire canal if walls are extremely thin and fragile
3. Coronal restoration:
   • Bond composite resin to restore fractured incisal edge and access cavity
   • If tooth severely weakened → full coverage ceramic crown or fibre post + crown (though post placement in thin-walled immature teeth is controversial)

• Completed in 2–3 visits
• No prolonged dentinal weakening
• Strong evidence base; endorsed by AAE guidelines

Option 3: Regenerative Endodontic Procedure (REP) / Pulp Revascularisation ⭐⭐ (Biologically Ideal — Most Recommended for This Patient)

• Only treatment that can achieve continued root development (lengthening + wall thickening)
• The Stem Cells of Apical Papilla (SCAP) survive pulp necrosis as they are located beyond the apex
• Hertwig's Epithelial Root Sheath may still be viable → potential for continued cementogenesis
• Strengthens the tooth against future fracture — the single greatest long-term risk in immature teeth

1. Anaesthesia: 3% Mepivacaine plain OR minimal adrenaline concentration — vasoconstrictors can compromise SCAP survival; rubber dam
2. Access preparation; minimal/no instrumentation of canal walls
3. Irrigation protocol (critical):
   • 1.5% NaOCl (reduced from standard 5.25% — preserves SCAP viability; full strength is cytotoxic to stem cells)
   • 17% EDTA — removes smear layer AND releases growth factors (BMPs, FGFs, TGF-β) from dentinal matrix to support stem cell differentiation
   • Final irrigant: 17% EDTA (not NaOCl)
4. Dry with paper points
5. Intracanal medicament — choose one:
   • Double Antibiotic Paste (DAP): Ciprofloxacin + Metronidazole (1:1) — preferred for anterior teeth to avoid minocycline-induced crown discolouration
   • Triple Antibiotic Paste (TAP): Ciprofloxacin + Metronidazole + Minocycline — effective but causes tooth discolouration (avoid in visible anterior teeth OR apply dentine bonding agent to crown dentine before placement to prevent staining)
   • Ca(OH)₂: Alternative if antibiotics not preferred
6. Seal with GIC temporary restoration; review at 3–4 weeks; prescribe systemic antibiotics if acute abscess

1. Confirm symptom resolution; remove antibiotic paste with thorough EDTA irrigation
2. Induce bleeding into canal (scaffold):
   • Administer anaesthesia without vasoconstrictor (e.g., 3% mepivacaine) to preserve blood flow
   • Insert a sterile pre-curved K-file or endodontic explorer 2–3 mm beyond the apex into periapical tissue
   • Lacerate periapical vessels → allow blood to fill canal slowly to 3 mm below CEJ
   • Allow 15 minutes for blood clot formation
   • Alternative scaffolds if bleeding difficult to control: PRP (Platelet Rich Plasma) or PRF (Platelet Rich Fibrin) — centrifuged from patient's own blood; contain high concentrations of growth factors (PDGF, VEGF, TGF-β)
3. Collagen sponge placed over clot if needed to stabilise
4. Place white MTA (4 mm) or Biodentine over scaffold at CEJ level — coronal seal/barrier
   • White MTA preferred over grey in anterior teeth (less discolouration)
   • Biodentine increasingly favoured — sets faster, less discolouration, comparable bioactivity
5. GIC base over MTA → allow to set
6. Definitive composite resin restoration — restores fractured incisal edge + seals access

• Continued root lengthening
• Thickening of dentinal walls (reduced fracture risk)
• Apical foramen closure / narrowing
• Resolution of periapical radiolucency
• Sinus tract disappearance (usually within 4–6 weeks of disinfection)

Treatment Comparison Summary

Adjunct Management

• Acute pain/abscess: Amoxicillin 500 mg TDS × 5–7 days + Ibuprofen 400 mg TDS (anti-inflammatory and analgesic)
• Sinus tract: Will resolve spontaneously once the source of infection (necrotic canal) is eliminated — no surgical intervention needed
• Crown discolouration: Internal bleaching (sodium perborate + water walking bleach technique) can be performed after successful REP if aesthetics remain a concern
• Fractured incisal edge: Composite resin restoration (direct build-up with palatal silicone index from study model) — after endodontic treatment
• Sports protection: Custom-fabricated mouthguard to prevent recurrent trauma
• Long-term follow-up: Radiographic review at 6, 12, 18, 24 months — monitor root development, periapical healing, absence of symptoms

Conclusion

A1.1 Clinical Features and Complications of Type 2 Diabetes Mellitus and Periodontitis (3 Marks)

Type 2 Diabetes Mellitus — Clinical Features

• Polyuria — osmotic diuresis from glucosuria
• Polydipsia — compensatory response to fluid loss
• Polyphagia — cellular starvation despite hyperglycaemia
• Fatigue, weight gain (80% of T2D patients are obese)
• Often asymptomatic at diagnosis — discovered incidentally on routine screening
• Acanthosis nigricans — velvety hyperpigmentation at skin folds (marker of insulin resistance)
• Recurrent infections — urinary tract, skin, oral fungal infections (impaired neutrophil function)

• Fasting plasma glucose ≥126 mg/dL (7.0 mmol/L)
• 2-hour glucose ≥200 mg/dL on OGTT
• HbA1c ≥6.5%
• Random glucose ≥200 mg/dL with symptoms

Complications of Type 2 Diabetes Mellitus

"Formation of AGEs, activation of protein kinase C (PKC), disturbances in the polyol pathways, and overload of the hexosamine pathway" — Robbins, Cotran & Kumar Pathologic Basis of Disease

Microvascular Complications:

Macrovascular Complications:

• Atherosclerosis — accelerated; ischaemic heart disease (2–4× increased risk of MI), stroke, peripheral arterial disease
• Hypertension — present in ~75% of T2D patients
• Dyslipidaemia — elevated triglycerides, low HDL, small dense LDL

Other Complications:

• Diabetic foot — neuropathy + ischaemia + impaired wound healing → ulceration, Charcot foot, amputation
• Impaired immunity — reduced neutrophil chemotaxis, phagocytosis, and oxidative burst → susceptibility to infections
• Non-alcoholic fatty liver disease (NAFLD)
• Periodontal disease — recognised as the "sixth complication" of diabetes

Periodontitis — Clinical Features

• Gingival erythema, oedema, and bleeding on probing (BOP) — hallmark of gingival inflammation
• Increased probing pocket depth (PPD) — ≥4 mm pathological pockets
• Clinical attachment loss (CAL) — irreversible loss of connective tissue attachment
• Alveolar bone loss — horizontal or vertical pattern on radiographs
• Tooth mobility and eventual tooth loss in advanced disease
• Gingival recession — exposure of root surfaces
• Suppuration from periodontal pockets
• Halitosis
• Often painless until advanced stages
• In diabetics: more severe, rapidly progressing, refractory to conventional treatment, multiple abscesses

A1.2 The Bidirectional Relationship Between Diabetes and Periodontal Disease (3 Marks)

Direction 1: Diabetes Worsens Periodontitis

• Chronic hyperglycaemia suppresses neutrophil chemotaxis, phagocytosis, and intracellular killing of periodontal pathogens → reduced ability to control the subgingival biofilm
• Altered monocyte/macrophage function — exaggerated pro-inflammatory cytokine response (↑ TNF-α, IL-1β, IL-6) to periodontal bacteria → excessive tissue destruction

• Hyperglycaemia causes non-enzymatic glycation of proteins and lipids, forming AGEs
• AGEs bind to their receptor RAGE on endothelial cells, macrophages, and fibroblasts
• AGE-RAGE interaction → ↑ NF-κB activation → sustained pro-inflammatory cytokine production → collagen degradation → alveolar bone loss
• AGEs also crosslink collagen in the periodontal ligament → impaired tissue repair and regeneration

• Microangiopathy reduces oxygen and nutrient delivery to periodontal tissues
• Thickened basement membranes → impaired leukocyte migration to sites of infection
• Impaired angiogenesis post-infection → delayed wound healing

• Elevated gingival crevicular fluid glucose in diabetics provides a substrate-rich environment favouring growth of pathogenic anaerobes (e.g., Porphyromonas gingivalis, Tannerella forsythia)
• Shifts microbiome toward greater virulence

• Reduced fibroblast proliferation and collagen synthesis
• Increased matrix metalloproteinase (MMP) activity → accelerated collagen breakdown
• Reduced growth factor activity (PDGF, TGF-β) → impaired periodontal tissue regeneration

Direction 2: Periodontitis Worsens Glycaemic Control

• Periodontitis is a chronic low-grade infection; subgingival bacteria and their products (LPS) enter the systemic circulation
• This triggers a systemic acute-phase response — elevated CRP, fibrinogen, IL-6, TNF-α
• TNF-α directly interferes with insulin receptor signalling — phosphorylation of IRS-1 serine residues → impairs GLUT-4 translocation → worsened peripheral insulin resistance

• IL-6 and TNF-α from the inflamed periodontium act on adipocytes and hepatocytes
• ↑ hepatic glucose production and ↓ peripheral glucose uptake → sustained hyperglycaemia
• Comparable to the inflammatory mechanism by which visceral obesity causes insulin resistance

• Periodontal inflammation elevates serum lipids (↑ triglycerides) → contributes to the dyslipidaemia already present in T2D

• Multiple systematic reviews and meta-analyses demonstrate that successful periodontal treatment reduces HbA1c by approximately 0.36–0.65% — clinically meaningful and comparable to adding a second oral hypoglycaemic agent
• The Treat Periodontitis and Improve Diabetes Outcomes (TOPIDS) and similar trials confirm this relationship

Summary of Bidirectional Relationship

Hyperglycaemia (T2D)
        ↓
↑ AGEs, ↓ Neutrophil function, Microangiopathy
        ↓
More severe / refractory Periodontitis
        ↓
↑ Systemic TNF-α, IL-6, LPS
        ↓
↑ Insulin resistance → ↑ HbA1c → Worsened T2D
        ↗ (feeds back)

A1.3 Current Guidelines for Managing Diabetic Patients in Dental Practice (4 Marks)

Pre-Treatment Assessment

• Document type of diabetes, duration, current medications (insulin, metformin, sulfonylureas, GLP-1 agonists, SGLT-2 inhibitors)
• Record most recent HbA1c — the gold standard of glycaemic control:
  • HbA1c <7% → well-controlled → routine dental care with standard precautions
  • HbA1c 7–9% → moderately controlled → proceed with care, liaise with physician
  • HbA1c >9% → poorly controlled → defer elective procedures; emergency care only; prioritise glycaemic stabilisation
• Note frequency of hypoglycaemic episodes, recent blood glucose readings
• Record associated complications (nephropathy, neuropathy, cardiovascular disease) — these affect anaesthetic and drug choices

• Recommend checking blood glucose before dental procedures (especially surgical)
• Safe range for dental treatment: 70–180 mg/dL (3.9–10 mmol/L)
• If blood glucose <70 mg/dL (hypoglycaemia): postpone treatment, administer 15g fast-acting carbohydrate (glucose tablets/orange juice), recheck after 15 minutes
• If blood glucose >400 mg/dL: defer elective treatment; refer to physician

Appointment Planning

• Schedule in the morning — cortisol levels are higher in the morning, providing better stress response; patients with T2D often have better glycaemic control in morning hours
• Avoid fasting patients — ensure patient has eaten normally and taken medications before the appointment
• Keep appointments short to moderate duration — prolonged stress elevates counter-regulatory hormones (cortisol, glucagon) → hyperglycaemia
• Do not skip meals — instruct patients not to fast unless general anaesthesia is planned

• Local anaesthetics with vasoconstrictors (adrenaline): Use with caution; small doses (e.g., 2 cartridges of 1:100,000 adrenaline) are generally safe in well-controlled diabetics. Adrenaline can transiently raise blood glucose — avoid in poorly controlled patients
• NSAIDs (e.g., ibuprofen): Use cautiously in patients with diabetic nephropathy (reduced renal function) — can worsen renal function
• Steroids (corticosteroids): Avoid unless essential — significantly elevate blood glucose
• Metformin + contrast media: If referring for imaging, inform the radiologist (metformin should be withheld 48 hours before iodinated contrast)
• Antibiotic prophylaxis: Not routinely required for T2D alone; indicated if immunocompromised or poorly controlled (consider amoxicillin or clindamycin for surgical procedures)

Periodontal Management (Core of Dental Care)

• Thorough periodontal assessment at every visit — probing depths, BOP, CAL, bone levels
• Non-surgical periodontal therapy (NSPT) — scaling and root planing (SRP) / debridement is the first-line treatment for periodontitis in diabetic patients
  • Evidence: SRP reduces HbA1c by ~0.36–0.65% — communicate this benefit to patients and physicians
• Adjunctive systemic antibiotics (e.g., doxycycline 100 mg OD × 2 weeks) may be considered for poorly controlled diabetics with severe periodontitis, as they reduce the systemic bacterial/inflammatory load more effectively
• Sub-antimicrobial dose doxycycline (SDD) — 20 mg BD — inhibits MMP activity, reduces collagen destruction without antibiotic effects
• Maintenance therapy: Recall every 3 months (rather than standard 6-month interval) for diabetic patients — more frequent monitoring due to increased disease susceptibility

Wound Healing and Surgical Considerations

• Elective periodontal surgery, implant placement, extractions: defer if HbA1c >9% until glycaemic control improves
• Inform the patient's physician/endocrinologist before major oral surgical procedures
• Post-surgical healing is delayed in diabetics — extend antibiotic cover post-operatively if indicated; use resorbable sutures
• Implants: Success rates are lower in poorly controlled diabetics; achievable in well-controlled patients (HbA1c <7–8%) with careful planning

Patient Communication and Interdisciplinary Collaboration

• Explain the bidirectional link to patients — treating periodontal disease can help improve blood sugar control (motivational for compliance)
• Reinforce meticulous oral hygiene — powered toothbrushes, interdental aids, twice-daily fluoride toothpaste
• Advise on xerostomia (dry mouth) — common in diabetics due to polyuria and autonomic neuropathy; recommend saliva substitutes, frequent water intake, sugarless gum
• Screen for oral candidiasis (angular cheilitis, denture stomatitis) — common in diabetics; treat with topical antifungals (miconazole, nystatin)

• Establish communication with the patient's general medical practitioner/endocrinologist
• Share periodontal findings and treatment plans — joint management improves both glycaemic and periodontal outcomes
• The 2017 EFP/AAP World Workshop and the International Diabetes Federation (IDF) jointly recommend that periodontal assessment be part of routine diabetes care, and that diabetic patients be referred for periodontal evaluation as standard practice

Summary Guidelines Table

"Duration of DM and degree of glycemic control are the best predictors of the development of [complications]" — Harrison's Principles of Internal Medicine, 22nd Ed., p.3267

Essay: Interlinking Pathways — The Bidirectional Relationship Between Diabetes Mellitus and Periodontal Disease

Introduction

A1.1 Clinical Features and Complications of Type 2 Diabetes Mellitus and Periodontitis (3 Marks)

Type 2 Diabetes Mellitus

• Diabetic retinopathy — the leading cause of new-onset blindness between ages 20–74. Ranges from nonproliferative (microaneurysms, haemorrhages, cotton-wool spots) to proliferative disease (neovascularisation, vitreous haemorrhage, retinal detachment) — Harrison's Principles of Internal Medicine, 22nd Ed.
• Diabetic nephropathy — the leading cause of end-stage renal disease (ESRD); affects 20–40% of diabetics. Characterised by glomerular hyperfiltration → basement membrane thickening → progressive albuminuria → declining GFR — Harrison's
• Diabetic neuropathy — peripheral (glove-and-stocking sensory loss, foot ulceration), autonomic (gastroparesis, erectile dysfunction, postural hypotension), and mononeuropathy forms

• Coronary heart disease — the leading cause of death in T2D; diabetes significantly increases risk of acute MI, often presenting silently ("silent ischaemia") due to autonomic neuropathy
• Cerebrovascular disease — increased stroke risk
• Peripheral artery disease — contributes to diabetic foot, gangrene, and amputation

Periodontitis — Clinical Features and Complications

• Gingival erythema, oedema, and bleeding on probing (BOP) — cardinal signs of gingival inflammation
• Pathological probing pocket depths (PPD ≥4 mm) — formation of periodontal pockets as junctional epithelium migrates apically
• Clinical attachment loss (CAL) — the definitive marker of irreversible periodontal destruction; used for staging severity (Stage I–IV per 2017 Classification)
• Radiographic alveolar bone loss — horizontal or angular/vertical patterns
• Tooth mobility and pathological migration in advanced stages
• Gingival recession, suppuration from pockets, halitosis
• Often painless until advanced — contributing to late presentation

A1.2 Clinical Implications of the Bidirectional Relationship Between Diabetes and Periodontal Disease (3 Marks)

Direction 1 — How Diabetes Worsens Periodontitis

Direction 2 — How Periodontitis Worsens Glycaemic Control

Summary of Bidirectional Pathways

Hyperglycaemia (T2DM)
       ↓
↑ AGEs/RAGE → NF-κB → ↑ TNF-α, IL-1β
↓ Neutrophil function
Microangiopathy, impaired healing
       ↓
More severe, refractory Periodontitis
       ↓
↑ Systemic LPS, TNF-α, IL-6
       ↓
↑ Insulin resistance → ↑ HbA1c
       ↗ (feeds back to worsen T2DM)

A1.3 Current Guidelines and Recommendations for Managing Diabetic Patients in Dental Practice (4 Marks)

1. Pre-Treatment Medical Assessment

• Obtain a full medical history including type of DM, duration, current medications (metformin, sulphonylureas, insulin, GLP-1 agonists, SGLT-2 inhibitors), recent HbA1c, frequency of hypoglycaemic episodes, and presence of diabetes complications
• Chair-side blood glucose monitoring before surgical or complex procedures:
  • Safe treatment range: 70–180 mg/dL
  • Blood glucose <70 mg/dL (hypoglycaemia): postpone procedure; administer 15 g fast-acting carbohydrate (glucose tablets/fruit juice); recheck after 15 minutes
  • Blood glucose >400 mg/dL: defer elective treatment; refer for urgent medical review

2. Appointment Planning and Patient Preparation

• Schedule appointments in the morning — cortisol levels provide better stress buffering; glycaemic levels are typically more stable
• Ensure the patient has eaten normally and taken routine medications before the appointment — do not allow diabetic patients to attend fasted for routine dental care
• Keep appointments brief — prolonged procedural stress elevates catecholamines and cortisol, driving counter-regulatory hyperglycaemia
• Have fast-acting glucose readily available (glucose gel, orange juice) at the dental chair in case of intra-operative hypoglycaemia

3. Pharmacological Considerations

• Local anaesthetics with vasoconstrictors: Use in conservative quantities — up to 2 cartridges of 1:100,000 adrenaline is generally safe in well-controlled T2DM. Adrenaline can transiently elevate blood glucose by stimulating glycogenolysis; minimise dose in poorly controlled patients
• NSAIDs (e.g., ibuprofen): Use cautiously in patients with diabetic nephropathy — may further reduce already compromised renal function; prefer paracetamol for analgesia in such patients
• Corticosteroids: Avoid unless strictly necessary — produce significant acute hyperglycaemia and can precipitate hyperosmolar states
• Antibiotic prescribing: Not routinely required for T2DM alone; indicated perioperatively for poorly controlled patients (HbA1c >9%), immunocompromised status, or evidence of spreading infection — amoxicillin 500 mg TDS or clindamycin 300 mg TDS (if penicillin allergic) for 5–7 days
• Metformin: Inform radiologists if the patient is referred for procedures requiring iodinated contrast — metformin should be withheld 48 hours pre/post-contrast to prevent lactic acidosis in the setting of contrast-induced renal impairment

4. Periodontal Management — Core Clinical Protocol

• Comprehensive periodontal assessment at every visit for all known diabetic patients: probing depths, BOP, CAL, radiographic bone levels, mobility
• Screen for undiagnosed diabetes in patients presenting with severe/rapidly progressing periodontitis — request HbA1c or fasting plasma glucose if systemic risk factors are present
• Non-surgical periodontal therapy (NSPT) — full-mouth scaling and root planing (SRP) — as the first-line treatment:
  • Reduces HbA1c by ~0.4–0.65% in T2DM patients at 3 months
  • Reduces systemic CRP, TNF-α, and IL-6 levels
  • Communicate this systemic benefit explicitly to patients and their physicians
• Adjunctive systemic antibiotics (doxycycline 100 mg OD × 2 weeks, or metronidazole + amoxicillin) may be considered in poorly controlled diabetics with Stage III–IV periodontitis to maximise infection control
• Sub-antimicrobial dose doxycycline (SDD, 20 mg BD) — inhibits MMP-mediated collagen degradation without antibiotic effect; useful adjunct in chronic periodontitis
• Periodontal maintenance recall: Every 3 months for diabetic patients (rather than the standard 6-month interval) — increased susceptibility necessitates closer monitoring

5. Surgical Procedures

• Elective periodontal surgery, implant placement, and extractions should be deferred until HbA1c ≤9%
• Inform the patient's physician/endocrinologist before major oral surgical procedures — coordinate insulin dose adjustments if needed
• Implants: achievable in well-controlled T2DM (HbA1c <7–8%) with careful case selection; evidence shows comparable long-term survival to non-diabetics when glycaemia is optimised
• Post-surgical healing is delayed — use resorbable sutures, extend antibiotic cover if indicated, schedule close post-operative review

6. Patient Education and Oral Hygiene Instruction

• Explain the bidirectional relationship in accessible terms: "Treating your gum disease can help your blood sugar, and better blood sugar control helps your gum disease respond to treatment" — this is a powerful motivator for adherence
• Demonstrate and reinforce meticulous oral hygiene: modified Bass brushing technique, interdental cleaning (floss/interdental brushes), twice-daily fluoride toothpaste
• Screen for and manage xerostomia (dry mouth) — common in T2DM due to polyuria-driven dehydration and autonomic neuropathy; recommend saliva substitutes, frequent water sipping, sugarless xylitol gum
• Screen for oral candidiasis (angular cheilitis, denture stomatitis, pseudomembranous candidiasis) — endemic in poorly controlled diabetics; treat with topical miconazole or nystatin

7. Interdisciplinary Collaboration

• The IDF and EFP (2022 joint guidelines) explicitly recommend that all diabetic patients be referred for periodontal evaluation as part of routine diabetes care, and vice versa — all patients with severe periodontitis should be screened for T2DM
• Establish direct communication with the patient's general medical practitioner or endocrinologist: share periodontal findings, treatment outcomes, and HbA1c response data
• Dental professionals should document HbA1c values in patient records and flag cases where periodontal disease may be contributing to refractory hyperglycaemia for physician review

Conclusion

Clinical Features and Complications of Type 2 Diabetes Mellitus and Periodontitis

PART A: Type 2 Diabetes Mellitus

Clinical Features

• Polyuria — osmotic diuresis secondary to glucosuria
• Polydipsia — compensatory response to fluid and electrolyte losses
• Polyphagia — cellular glucose starvation despite systemic hyperglycaemia
• Fatigue and weakness — impaired cellular energy metabolism
• Blurred vision — osmotic changes in the lens
• Slow wound healing and recurrent infections — impaired neutrophil function and vascular compromise
• Acanthosis nigricans — velvety hyperpigmentation at skin folds; marker of insulin resistance
• Often asymptomatic — diagnosed on routine blood screening; insidious onset distinguishes T2DM from T1DM

Complications of Type 2 DM

Microvascular Complications:

Macrovascular Complications:

• Coronary heart disease — leading cause of death in T2DM; MI frequently presents atypically or silently due to autonomic neuropathy
• Cerebrovascular disease — increased stroke risk (2–4×)
• Peripheral arterial disease — lower limb ischaemia, diabetic foot ulceration, gangrene, amputation

Acute Complications:

• Hyperosmolar Hyperglycaemic State (HHS) — non-ketotic; blood glucose >600 mg/dL; altered consciousness; high mortality
• Hypoglycaemia — most commonly iatrogenic (sulphonylureas, insulin therapy)

Oral Complications:

• Periodontal disease — the recognised sixth complication of diabetes
• Xerostomia, oral candidiasis, impaired wound healing, burning mouth syndrome

PART B: Periodontitis

Clinical Features

• Deeper pockets, greater attachment loss, more rapid bone destruction
• Multiple periodontal abscesses
• Poor and slow response to conventional periodontal therapy
• Higher tooth loss rates compared to normoglycaemic individuals

Complications of Periodontitis

Local/Oral Complications:

• Tooth loss — end-stage outcome of uncontrolled periodontitis; primary cause of tooth loss in adults over 35
• Periodontal abscess — acute suppurative infection within the periodontal pocket; pain, swelling, sinus tract formation
• Endodontic-periodontal lesions — combined pulpal and periodontal breakdown via lateral canals or apical foramen
• Occlusal trauma — secondary to tooth migration and mobility
• Aesthetic compromise — black triangles from papilla loss, recession, spacing

Systemic Complications (Oral-Systemic Link):

Summary

The two conditions share a common inflammatory microenvironment — making simultaneous medical and periodontal management essential for optimal outcomes in affected patients.

Clinical Features and Complications of Type 2 DM and Periodontitis — Tabular Format

Table 1: Clinical Features

Table 2: Complications

Table 3: Comparison at a Glance

Clinical Implications of the Bidirectional Relationship Between Diabetes and Periodontal Disease

Overview

Table 1: Direction 1 — How Diabetes Worsens Periodontal Disease

• 2–3× greater risk of developing periodontitis
• More severe attachment loss, deeper pockets, more rapid bone loss
• Multiple, recurrent periodontal abscesses
• Refractory periodontitis — poor treatment response
• Higher rates of tooth loss

Table 2: Direction 2 — How Periodontitis Worsens Glycaemic Control

• Untreated periodontitis raises HbA1c by approximately 0.4–0.65%
• May explain why some diabetic patients fail to achieve glycaemic targets despite appropriate medical therapy
• Successful periodontal treatment (SRP) reduces HbA1c by ~0.36–0.65% — comparable to adding a second oral hypoglycaemic agent

Table 3: Shared Pathological Pathways — Common Ground

Table 4: Direct Clinical Implications for Practice

Table 5: Implications for Interdisciplinary Collaboration

Summary Diagram — Bidirectional Cycle

       ┌──────────────────────────────────────┐
       │         TYPE 2 DIABETES              │
       │  Hyperglycaemia → AGEs, ↓ Immunity   │
       │  Microangiopathy, ↑ MMP activity      │
       └──────────────┬───────────────────────┘
                      │ Worsens ↓
       ┌──────────────▼───────────────────────┐
       │           PERIODONTITIS              │
       │  Deeper pockets, bone loss,          │
       │  abscesses, tooth loss               │
       └──────────────┬───────────────────────┘
                      │ Worsens ↑
       ┌──────────────▼───────────────────────┐
       │    ↑ Systemic TNF-α, IL-6, LPS       │
       │    ↑ Insulin resistance              │
       │    ↑ HbA1c → Worsened T2DM           │
       └──────────────────────────────────────┘
              (Perpetuating cycle)

Key clinical takeaway: Breaking this cycle requires treating both conditions simultaneously. Periodontal treatment alone can reduce HbA1c by ~0.4–0.65%; improved glycaemic control alone reduces periodontal severity. Combined management produces outcomes superior to treating either condition in isolation.